| アブストラクト | OBJECTIVES: To describe the prescribing trends of antihypertensive drugs in primary care patients and assess the trajectory of antihypertensive drug prescriptions, from first-line to third-line, in patients with hypertension according to changes to the United Kingdom (UK) hypertension management guidelines. DESIGN: Population-based cohort study. SETTING AND PARTICIPANTS: We used the UK Clinical Practice Research Datalink, an electronic primary care database representative of the UK population. Between 1988 and 2018, we identified all adult patients with at least one prescription for a thiazide diuretic, angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker, beta-blocker or calcium channel blocker (CCB). PRIMARY AND SECONDARY OUTCOME MEASURES: We estimated the period prevalence of patients with antihypertensive drug prescriptions for each calendar year over a 31-year period. Treatment trajectory was assessed by identifying patients with hypertension newly initiating an antihypertensive drug, and treatment changes were defined by a switch or add-on of a new class. This cohort was stratified before and after 2007, the year following important changes to UK hypertension management guidelines. RESULTS: The cohort included 2 709 241 patients. The prevalence of primary care patients with antihypertensive drug prescriptions increased from 7.8% (1988) to 21.9% (2018) and was observed for all major classes except thiazide diuretics. Patients with hypertension initiated thiazide diuretics (36.8%) and beta-blockers (23.6%) as first-line drugs before 2007, and ACE inhibitors (39.9%) and CCBs (31.8%) after 2007. After 2007, 17.3% were not prescribed guideline-recommended first-line agents. Overall, patients were prescribed a median of 2 classes (IQR 1-2) after first-line treatment. CONCLUSION: Nearly one-quarter of primary care patients were prescribed antihypertensive drugs by the end of the study period. Most patients with hypertension initiated guideline-recommended first-line agents. Not all patients, particularly females, were prescribed recommended agents however, potentially leading to suboptimal cardiovascular outcomes. Future research should aim to better understand the implication of this finding. |
|---|
| 組織名 | Department of Epidemiology, Biostatistics, and Occupational Health, McGill;University, Montreal, Quebec, Canada.;Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research,;Montreal, Quebec, Canada.;Division of General Internal Medicine, McGill University Health Centre, Montreal,;Quebec, Canada.;Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada.;Department of Family Medicine, McGill University, Montreal, Quebec, Canada.;Division of Clinical Epidemiology, McGill University Health Centre, Montreal,;Departmenf of Medicine, McGill University, Montreal, Quebec, Canada.;University, Montreal, Quebec, Canada laurent.azoulay@mcgill.ca.;Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec,;Canada. |
|---|
